Leveraging insights from cancer to improve tuberculosis therapy

作者：Meenal Datta, Laura E. Via, Véronique Dartois, Lei Xu, Clifton E. Barry, Rakesh K. Jain · 发表于：Trends in Molecular Medicine · 年份：2024 · DOI：10.1016/j.molmed.2024.07.011 · 被引用次数：7 · 研究领域：Tuberculosis Research and Epidemiology、Diagnosis and treatment of tuberculosis、Cancer Immunotherapy and Biomarkers

Exploring and exploiting the microenvironmental similarities between pulmonary tuberculosis (TB) granulomas and malignant tumors has revealed new strategies for more efficacious host-directed therapies (HDTs). This opinion article discusses a paradigm shift in TB therapeutic development, drawing on critical insights from oncology. We summarize recent efforts to characterize and overcome key shared features between tumors and granulomas, including excessive fibrosis, abnormal angiogenesis, hypoxia and necrosis, and immunosuppression. We provide specific examples of cancer therapy application to TB to overcome these microenvironmental abnormalities, including matrix-targeting therapies, antiangiogenic agents, and immune-stimulatory drugs. Finally, we propose a new framework for combining HDTs with anti-TB agents to maximize therapeutic delivery and efficacy while reducing treatment dosages, duration, and harmful side effects to benefit TB patients.